To Evaluate Hypertrichosis With Low Dose Oral Minoxidil and Spironolactone Combination Therapy for Alopecia
Author Type(s)
Student
Document Type
Article
Publication Date
8-12-2024
DOI
10.1007/s00403-024-03261-0
Journal Title
Archives of Dermatological Research
Abstract
Low dose oral minoxidil (LDOM) is an efficacious and safe treatment for alopecia, however, a notable side effect is hypertrichosis. Spironolactone, known for treating hirsutism, is also used off-label for the treatment of certain forms of alopecia and may reduce LDOM-induced hypertrichosis. We performed a retrospective review of 54 patients seen at NYU Langone Health and compared hypertrichosis rates in female alopecia patients on LDOM monotherapy versus those on combination therapy with spironolactone. Among 54 patients, 37 received LDOM alone and 17 received the combination. Hypertrichosis developed in 33.3% of patients, with lower rates in the combination group (17.6% vs. 40.5% for monotherapy). Although not statistically significant, the trend suggests spironolactone may mitigate hypertrichosis. The study highlights the potential of combination therapy to address hypertrichosis and calls for larger studies to confirm these findings.
Recommended Citation
Nohria, A., Desai, D., Sikora, M., Mandal, S., Caplan, A., Shapiro, J., & Sicco, K. (2024). To Evaluate Hypertrichosis With Low Dose Oral Minoxidil and Spironolactone Combination Therapy for Alopecia. Archives of Dermatological Research, 316 (8), 510-510. https://doi.org/10.1007/s00403-024-03261-0
